297 related articles for article (PubMed ID: 12244784)
1. [Osteoprotegrin and RANKL/RANK system: is it the future of bone metabolism?].
Ferrer Cañabate J; Tovar I; Martínez P
An Med Interna; 2002 Aug; 19(8):385-88. PubMed ID: 12244784
[No Abstract] [Full Text] [Related]
2. [Merger of bone biology and immunology].
Suda T; Shima N; Higashio K
Tanpakushitsu Kakusan Koso; 2002 Oct; 47(13):1837-43. PubMed ID: 12385106
[No Abstract] [Full Text] [Related]
3. The osteoprotegerin/osteoprotegerin ligand family: role in inflammation and bone loss.
Yeung RS
J Rheumatol; 2004 May; 31(5):844-6. PubMed ID: 15124240
[No Abstract] [Full Text] [Related]
4. Crystal structure of RANK ligand involved in bone metabolism.
Ito S; Hata T
Vitam Horm; 2004; 67():19-33. PubMed ID: 15110169
[TBL] [Abstract][Full Text] [Related]
5. [Molecular mechanism of bone metabolism].
Kotake S; Utagawa N; Suda T; Kamatani N
Nihon Naika Gakkai Zasshi; 2000 Oct; 89(10):2046-53. PubMed ID: 11215116
[No Abstract] [Full Text] [Related]
6. Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin.
Collin-Osdoby P
Circ Res; 2004 Nov; 95(11):1046-57. PubMed ID: 15564564
[TBL] [Abstract][Full Text] [Related]
7. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling.
Theoleyre S; Wittrant Y; Tat SK; Fortun Y; Redini F; Heymann D
Cytokine Growth Factor Rev; 2004 Dec; 15(6):457-75. PubMed ID: 15561602
[TBL] [Abstract][Full Text] [Related]
8. [Osteoprotegerin ligand and osteoprotegerin: new concepts of the pathogenesis and therapy of metabolic bone diseases].
Hofbauer LC; Heufelder AE
Dtsch Med Wochenschr; 2001 Feb; 126(6):145-50. PubMed ID: 11233883
[No Abstract] [Full Text] [Related]
9. Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system.
Tanaka S; Nakamura K; Takahasi N; Suda T
Immunol Rev; 2005 Dec; 208():30-49. PubMed ID: 16313339
[TBL] [Abstract][Full Text] [Related]
10. Osteoprotegerin, RANK, and RANK ligand: the good, the bad, and the ugly in rheumatoid arthritis.
Hofbauer LC; Heufelder AE; Erben RG
J Rheumatol; 2001 Apr; 28(4):685-7. PubMed ID: 11327234
[No Abstract] [Full Text] [Related]
11. Osteoclast precursors, RANKL/RANK, and immunology.
Xing L; Schwarz EM; Boyce BF
Immunol Rev; 2005 Dec; 208():19-29. PubMed ID: 16313338
[TBL] [Abstract][Full Text] [Related]
12. [Recent advance in basic research for osteoporosis].
Suda T; Miyaura C
Nihon Rinsho; 2004 Feb; 62 Suppl 2():13-20. PubMed ID: 15035090
[No Abstract] [Full Text] [Related]
13. Rheumatic diseases: the effects of inflammation on bone.
Walsh NC; Crotti TN; Goldring SR; Gravallese EM
Immunol Rev; 2005 Dec; 208():228-51. PubMed ID: 16313352
[TBL] [Abstract][Full Text] [Related]
14. Anti-RANKL therapy for inflammatory bone disorders: Mechanisms and potential clinical applications.
Anandarajah AP; Schwarz EM
J Cell Biochem; 2006 Feb; 97(2):226-32. PubMed ID: 16240334
[TBL] [Abstract][Full Text] [Related]
15. Interactive effect of interleukin-6 and prostaglandin E2 on osteoclastogenesis via the OPG/RANKL/RANK system.
Liu XH; Kirschenbaum A; Yao S; Levine AC
Ann N Y Acad Sci; 2006 Apr; 1068():225-33. PubMed ID: 16831922
[TBL] [Abstract][Full Text] [Related]
16. [Osteoclastogenesis Inhibitory Factor (OCIF) /Osteoprotegerin (OPG) as a new therapeutic agent for osteoporosis].
Mochizuki S; Kiyokawa A; Nagayama Y
Clin Calcium; 2005 Jan; 15(1):35-42. PubMed ID: 15632471
[TBL] [Abstract][Full Text] [Related]
17. Osteoprotegerin ligand and osteoprotegerin: novel implications for osteoclast biology and bone metabolism.
Hofbauer LC
Eur J Endocrinol; 1999 Sep; 141(3):195-210. PubMed ID: 10474114
[No Abstract] [Full Text] [Related]
18. Cytokines, osteoprotegerin, and RANKL in vitro and histomorphometric indices of bone turnover in patients with different bone diseases.
Siggelkow H; Eidner T; Lehmann G; Viereck V; Raddatz D; Munzel U; Hein G; Hüfner M
J Bone Miner Res; 2003 Mar; 18(3):529-38. PubMed ID: 12619938
[TBL] [Abstract][Full Text] [Related]
19. Bone cancer pain and the role of RANKL/OPG.
Clohisy DR; Mantyh PW
J Musculoskelet Neuronal Interact; 2004 Sep; 4(3):293-300. PubMed ID: 15615497
[TBL] [Abstract][Full Text] [Related]
20. Evidence of a role for RANKL in the development of myeloma bone disease.
De Leenheer E; Mueller GS; Vanderkerken K; Croucher PI
Curr Opin Pharmacol; 2004 Aug; 4(4):340-6. PubMed ID: 15251126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
